Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Future of Botulinum Toxin: New Types, Engineered Toxins, and GLP Effects
Description
The speaker reviews the future of botulinum toxin, focusing on new toxin types, engineered molecules, and possible GLP-related effects. Current cosmetic toxins are mostly type A, but newer options include type E, which has a much faster onset and shorter duration, and may be useful for patients wanting a trial treatment; studies suggest it can be followed safely by type A toxin without reducing later response. Other emerging toxins include a newly described type X and regionally developed products with unique sizes or manufacturing methods. A major theme is recombinant and engineered toxins, where heavy and light chains are mixed or modified to improve targeting, reduce spread, lower immunogenicity, and separate cosmetic effects from paralysis. These approaches may expand use into pain, migraine, wound healing, rosacea, acne, flushing, and scar prevention. The speaker also discusses a theoretical GLP connection: weight-loss patients may have altered toxin response due to reduced mass and receptor-related changes, possibly shortening duration, though evidence is early and mostly simulated rather than clinical. Overall, the field is moving toward faster, smarter, and more customizable toxins with broader medical and aesthetic applications.
View moreConclusions
- Next-generation botulinum toxins are being engineered to alter onset, duration, spread, and immunogenicity rather than simply repeat the effects of current type A products.
- Type E botulinum toxin appears to act much faster than traditional type A toxins but wears off much sooner, making it potentially useful when brief, testable effects are desired.
- Early data suggest that sequential use of botulinum toxin E followed by onabotulinumtoxinA remains safe and does not reduce later responsiveness to standard toxin treatments.
- Recombinant and engineered toxins may allow clinicians to separate sensory or therapeutic effects from muscle paralysis, expanding botulinum toxin use into pain, bladder symptoms, wound healing, and other non-cosmetic indications.
- Improved manufacturing strategies and recombinant designs may reduce contaminating proteins and therefore lower immunogenicity and antibody formation.
- Some newer toxin formulations show promising efficacy in glabellar lines and may offer comparable or even improved clinical responses with acceptable safety profiles.
- The broader future of botulinum toxin likely includes smarter, indication-specific molecules rather than one uniform treatment for all uses.
- Botulinum toxin may influence pathways outside the neuromuscular junction, including sensory neurotransmitters, inflammation, autonomic function, gland activity, and tissue healing.
- GLP-1 receptor agonist use may shorten botulinum toxin durability in some patients, although current evidence is mostly computational and not yet strongly confirmed in routine practice.
- Overall, the field is moving toward more specialized toxins and combination strategies that could improve precision, reduce side effects, and broaden therapeutic applications.
- Pediatric drugs. Springer, 2019.
- Yoelin, Dhawan et al. Plast Reconstr Surg. 2018.
- Hanke, Kaufman, Dayan et al. Poster presented AMWC, 2026.
- Ryuji Kaji. Toxicon, 2023.
- Ibrahim, H.; Retailleau, K., et al. A Novel Catalytically inactive Construct of Botulinum Neurotoxin A (BoNT/A) Directly Inhibits Visceral Sensory Signalling. Toxins, 2024.#10.3390/toxins16010030
- Dolly et al. Curr Opin Pharm. 2012.
- Escargueil, Popoff. Toxins. Dec 2020.
- Qingfeng Li, Xiao Long et al. Safety and Efficacy of Recombinant Botulinum Toxin A for moderate to severe glabellar lines. Plast Reconstr Surg, 2026.
- KFF Health Tracking Poll, May 2024.
- Galderma MAC Research, 2024.
- Eqram Rahman, Alain Michon, Parinitha Rao, Munim Ahmed, John H. Joseph, Woffles TL Wu, Jean DA. Carruthers, and William Richard Webb. Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications. Toxicon, 2026.#10.1016/j.toxicon.2025.108638